Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/138571
Title: | Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees |
Author: | Segarra, Ignacio Modamio Charles, Pilar Fernández Lastra, Cecilia Mariño Hernández, Eduardo L. |
Keywords: | Farmacocinètica Bioètica Diferències entre sexes Pharmacokinetics Bioethics Sex differences |
Issue Date: | 2017 |
Publisher: | Frontiers Media |
Abstract: | The efforts toward individualized medicine have constantly increased in an attempt to improve treatment options. These efforts have led to the development of small molecules which target specific molecular pathways involved in cancer progression. We have reviewed preclinical studies of sunitinib that incorporate sex as a covariate to explore possible sex-based differences in pharmacokinetics and drug-drug interactions (DDI) to attempt a relationship with published clinical outputs. We observed that covariate sex is lacking in most clinical outcome reports and suggest a series of ethic-based proposals to improve research activities and identify relevant different sex outcomes. We propose a deeper integration of preclinical, clinical, and translational research addressing statistical and clinical significance jointly; to embed specific sexdivergent endpoints to evaluate possible gender differences objectively during all stages of research; to pay greater attention to sex-divergent outcomes in polypharmacy scenarios, DDI and bioequivalence studies; the clear reporting of preclinical and clinical findings regarding sex-divergent outcomes; as well as to encourage the active role of scientists and the pharmaceutical industry to foster a new scientific culture through their research programs, practice, and participation in editorial boards and Institutional Ethics Review Boards (IRBs) and Research Ethics Committees (RECs). We establish the IRB/REC as the centerpiece for the implementation of these proposals. We suggest the expansion of its competence to follow up clinical trials to ensure that sex differences are addressed and recognized; to engage in data monitoring committees to improve clinical research cooperation and ethically address those potential clinical outcome differences between male and female patients to analyze their social and clinical implications in research and healthcare policies. Keywords: sunitinib, sex-divergent pharmacokinetics, clinical outcomes, covariate sex, research ethics, IRB, ELSI |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fphar.2017.00488 |
It is part of: | Frontiers in Pharmacology, 2017, vol. 8, p. 488 |
URI: | http://hdl.handle.net/2445/138571 |
Related resource: | https://doi.org/10.3389/fphar.2017.00488 |
ISSN: | 1663-9812 |
Appears in Collections: | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
678889.pdf | 461.83 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License